Search results
Results from the WOW.Com Content Network
But the pharma giant's launch of 19 products over a period of 18 months -- the most ever in such a short time -- should result in growth drivers to power revenue throughout this decade.
Derek Lowe is a medicinal chemist working on preclinical drug discovery in the pharmaceutical industry. Lowe has published a blog about this field, "In the Pipeline", since 2002 [ 1 ] and is a columnist for the Royal Society of Chemistry 's Chemistry World .
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
The index includes companies in pharmaceuticals, equipment and supplies, health-care providers and biotechnology, among others. 5-year returns (annualized): 12.4 percent Expense ratio: 0.09 percent
With the pandemic years in the rearview mirror, some of the best pharma stocks should continue to perform well. For one, by 2030, the pharma industry could be worth nearly $1.6 trillion, according ...
Regulatory developments, FDA/EMEA news, market legislation, pharma market movements, reviews of current and proposed legislation and regulation, conference details, and write-ups. Barbara Obstoj is the Managing Editor, which in 2009 acquired the archives of The Pharma Marketletter, a publication Barbara owned since 1991 and prior to that edited ...
In this article, we will discuss the 11 best pharma and biotech stocks to buy according to Jim Simons’ Euclidean Capital. If you want to skip our detailed analysis of Simons’ history ...